Discover and read the best of Twitter Threads about #Bebtelovimab

Most recents (7)

Status of the latest #COVID19 Wave in #NewYork #BellwetherState

NY just uploaded 425 sequences - had to update charts!

Top circulating variants - BA.5.2.1 (20%), BA.4.6 (15%)

Proportion of BQ* lineages are increasing
BQ.1* (2.84%) & BQ.1.1* (1.00%)👀 ImageImage
BQ.1.1 (aka #Cerberus) is able to evade all available mAb therapeutics including #Evusheld and #Bebtelovimab.

Bivalent boosters (OG/Omicron.BA.5) will potentially protect the boosted from getting severe disease.

Please get #boosted ASAP! Image
We may have to switch to #SequenceToTreat from #TestToTreat soon...

mAbs work well against BA.2.3.20

#Bebtelovimab works well against most BA.2.75* without spike K444 mutations

None of the mAb currently authorized by @US_FDA will work against BQ.1. lineage
Read 4 tweets
Lineages to watch

1. BQ.1*
2. BQ1.1*
3. BA.2.75.2*
4. XBB - Recombinant of BJ.1 and BM.1.1.1
5. BA.2.3.20

All lineages have appreciable ACE2 affinity;
1-4 are highly immune evasive;
1 & 2 evade many therapeutics - #Evusheld and #Bebtelovimab…
Credits to Lineage Spotters/Proposers

BA.2.3.20 - @LongDesertTrain
BQ.1*/BQ.1.1* - @siamosolocani
BA.2.75.2 - @agamedilab
XBB - @CorneliusRoemer

and the #LineageWatch team for 24/7 tracking & monitoring…
BA.2.3.20 [ ⛳️to track Convergent Mutations]

@PangoNetwork Proposal/Background

H/T @LongDesertTrain…
Read 7 tweets




Read 31 tweets
New #PANGO designations - BA.2.*

BA.2.4Alias of B.1.1.529.2.4, #Singapore lineage

BA.2.5Alias of B.1.1.529.2.5, lineage in #Portugal and other countries

BA.2.6Alias of B.1.1.529.2.6, lineage in #France and other countries

BA.2.7Alias of B.1.1.529.2.7, #USA lineage ImageImage
These are new designations - branching from the BA.2 subvariant

more to follow ..... will update key mutational differences and transmission advantage (if any)
BA.2.4 (aka B.1.1.529.2.4) | prevalent in Singapore

Key mutation: ORF6:M58K

COV-spectrum predicts a growth advantage of 14% over BA.2 and 46% over BA.1.1 in #Singapore

BA.2 and BA.1.1 are currently the dominant lineages in circulation in Singapore Image
Read 29 tweets
Recap settimanale su Covid: vediamo quello che è successo. Segue un thread con alcuni punti importanti, nel caso in cui ve li foste persi. Let's go!
1/n 🧵 #COVID19
Da una valutazione approfondita delle infezioni da BA.2 (>124.000 persone) vs BA.1 (>30.000) in Qatar sembrerebbe che BA.2 abbia cariche virali più elevate e periodi infettivi più lunghi.… 2/n
Hong Kong ha i decessi pro capite più alti al mondo causa Covid e continua a crescere. Preoccupante. 3/n
Read 16 tweets
👉👁️Variante BA.2, cada vez se conocen más detalles, no buenos. El monoclonal Sotrovimab, uno de nuestros únicos monoclonales, como tratamiento de Omicron, parece no efectivo con BA.2
👉👁️Evusheld parece no funcionar también con BA.2 Noticia, que esperemos no se confirme, supone un revés para los inmunodeprimidos. Realmente es marzo el momento de levantar toda restricción?
👉Los inmunodeprimidos responden de manera muy dispar a las vacunas, de ahí que necesiten tratamientos (monoclonales, antivirales), para poder vivir más tranquilos.
Read 5 tweets
BA.2 is a sublineage of Omicron that's replacing the original BA.1 version in the U.S. I'll break down what we know about its effects on current antivirals and the facts behind #bebtelovimab, the newest anti-SARS-CoV-2 monoclonal antibody (mAb) that received FDA EUA. a🧵 1/
Compared to BA.1, BA.2 has quite a few changes to ORF1ab and the NTD region of Spike. Luckily, I don't see any mutations in nsp5 or 12 that would affect Paxlovid, remdesivir, or molnupiravir activity 2/
The other good news pertains to Evusheld (tix/cil). It took a hit vs BA.1/BA.1.1, but based on data from David Ho's group (…), BA.2 has almost no effect on cilgavimab (CoV2-2130, blue box). This is great news for Evusheld and for our immunosuppressed pts 3/
Read 12 tweets

Related hashtags

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3.00/month or $30.00/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!